COVID-19 And Your Clinical Trials
-
UCB Uses Decentralized Trials To Manage Studies
2/16/2021
UCB has a long history of conducting trials in immunology and neurology, with an emphasis in epilepsy. According to Tero Laulajainen, VP and head of global clinical science and operations for UCB, the company has a broad range of therapeutic expertise and numerous global trials, including studies in China. Therefore, the company expected to be impacted when news of the COVID-19 virus first began to make headlines.
-
#NoGoingBack Supports Keeping Patients First
1/5/2021
#NoGoingBack has been gaining a lot of attention of late. Founded by Signant Health and supported (and chaired) by industry leaders like Craig Lipset of Clinical Innovation Partners and Allyson Small of SCRS, the group has been pushing for permanent adoption of the trial changes implemented in 2020 to keep patients safe from COVID-19 and drive often-discussed innovation into standard trial practice.
-
X4 Pharma Adjusts Clinical Trials For A COVID World
12/17/2020
With the COVID pandemic afflicting patients around the world, those with a compromised immune system are at even greater risk. X4 Pharma is currently conducting a global Phase 3 trial that was underway when the pandemic hit, and is for patients who are immunocompromised.
-
Lilly, Care Access Take COVID Trial Directly To Patients
12/10/2020
Eli Lilly and Company and Care Access Research have forged a unique partnership to develop and manage a first-of-its kind decentralized, mobile trial to safeguard the health of patients in nursing homes. Lilly and Care Access will take the trial directly to patients.
-
From Idea To Patient In 10 Weeks: NeuroRx’s Fast Track Approach
11/19/2020
Psychiatry is an area that Jonathan Javitt never planned to work in. In fact, he still jokes that he flunked a psychiatry class while in medical school. Unfortunately, life has a way of changing your focus. For Javitt, who is now the co-founder and CEO of NeuroRx, that happened 11 years ago when one of his closest friends approached him to say he was battling depression.
-
3 Steps To Get A Virtual Clinical Trial Up And Running
10/20/2020
Despite the existence of innovative technologies, they are only one piece of a complicated puzzle needed to successfully implement virtual clinical trial models. It’s critical that sponsors also consider these three key steps for achieving sustainable change in the bold, patient-centric move to virtual clinical trials.
-
Can Virtual Trials Maintain Their Momentum After COVID?
9/17/2020
Prior to COVID-19, there were many discussions about how it might be possible to conduct virtual trials, using technology and innovative measures. Now that the pandemic has forced many trials into virtual settings, what will it take for the industry to fully implement a virtual approach beyond the pandemic?
-
9 Factors For Driving Inclusivity & Patient Centricity In A Transformed Clinical Trials Landscape
9/15/2020
Patient-centricity, quality, and inclusion are not natural consequences of the shift to virtual clinical trials. To be intentional with the design, we must start with articulating and understanding the full contexts of patients’ lives, medical and beyond.
-
4 Best Practices That Kept A Biotech’s Clinical Trial Moving In The COVID-19 Era
8/12/2020
The timely enrollment and progression of clinical trials is critical for a pre-commercial biotech company, as delays can keep treatments from getting to patients and cost an organization significant money and reputation. When you throw in a worldwide pandemic, it’s a whole new ball game.
-
Regulatory Science & Clinical Research: Where Do We Stand (And Where Are We Going)?
7/14/2020
This article will share some thoughts on the current state of regulatory science, by reflecting back on two prominent meetings — the inaugural UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Summit and the Clinical Trials Transformation Initiative (CTTI) Virtual Meetings for Stakeholder Engagement on ICH E6.